SCHEMBL3944199

SCHEMBL3944199

[CH2]CN(C(N)=O)c1cccc(C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
RAB9A P51151 4/20 0.48
NPC1 O15118 3/20 0.48
PAX8 Q06710 2/20 0.48
JAK2 O60674 1/20 0.48
HTT P42858 1/20 0.48
TP53 P04637 1/20 0.46
GPX4 P36969 1/20 0.46
PARP1 P09874 1/20 0.44
SIGMAR1 Q99720 1/20 0.42
KMT2A Q03164 3/20 0.41
POLQ O75417 1/20 0.41
HPGD P15428 4/20 0.40
ALOX15 P16050 3/20 0.40
MAPT P10636 2/20 0.40
MEN1 O00255 2/20 0.40
USP2 O75604 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDM4E B2RXH2 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25751661 0.85 POLQ (0.51) ALDH1A1RAB9ANPC1PAX8JAK2
SCHEMBL9135583 0.82 RAB9A (0.50) ALDH1A1RAB9ANPC1PAX8JAK2
SCHEMBL14577832 0.82 ALDH1A1 (0.55) ALDH1A1RAB9ANPC1PAX8JAK2
SCHEMBL2058713 0.82 RAB9A (0.48) ALDH1A1RAB9ANPC1PAX8JAK2
SCHEMBL27897093 0.81 RAB9A (0.53) ALDH1A1RAB9ANPC1PAX8JAK2
SCHEMBL11651430 0.80 RAB9A (0.63) ALDH1A1RAB9ANPC1PAX8JAK2
SCHEMBL1416009 0.78 ALDH1A1 (0.48) ALDH1A1RAB9ANPC1PAX8HTT
SCHEMBL4606083 0.77 PARP1 (0.52) ALDH1A1RAB9ANPC1PAX8JAK2
SCHEMBL2668510 0.76 NPSR1 (0.44) ALDH1A1RAB9ANPC1PAX8JAK2
SCHEMBL13061841 0.76 RAB9A (0.54) ALDH1A1RAB9ANPC1PAX8JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538215-B2 Compounds which inhibit leukocyte adhesion mediated by VLA-4 ELAN PHARMACEUTICALS, INC. (US) 2009-05-26 US disclosed
US-20050261293-A1 Compounds which inhibit leukocyte adhesion mediated by VLA-4 WYETH 2005-11-24 US disclosed
US-6903088-B2 Compounds which inhibit leukocyte adhesion mediated by VLA-4 ELAN PHARMACEUTICALS, INC. (US) 2005-06-07 US disclosed
US-20030144328-A1 Compounds which inhibit leukocyte adhesion mediated by VLA-4 KONRADI ANDREI W (US) 2003-07-31 US disclosed
US-6479492-B1 TREATMENT OF INFLAMMATORY DISEASES IN A MAMMALIAN PATIENT ELAN PHARMACEUTICALS, INC. 2002-11-12 US disclosed
EP-1144384-A1 COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 Elan Pharmaceuticals, Inc. (US) 2001-10-17 EP disclosed
WO-2000043369-A1 COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 ELAN PHARMACEUTICALS, INC. (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261293-A1 Compounds which inhibit leukocyte adhesion mediated by VLA-4 VCAM1, ICAM1, CD4 ALDH1A1 322/4885RAB9A 2770/4885NPC1 3250/4885
US-20030144328-A1 Compounds which inhibit leukocyte adhesion mediated by VLA-4 VCAM1, ICAM1, CD4 ALDH1A1 322/4885RAB9A 2770/4885NPC1 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.